Evidence map›Paper›PMID 39231890›Full record

ArticleDrugs in R&D2024

Pharmacokinetics, Mass Balance, and Biotransformation of [

Shumao Ni, Sheng Ma, Yingying Yu, Zhenwen Yu, Yujia Zhu, Xiaofen Sun, Lin Li, Caixia Sun, Hui Wang, Peng Peng and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drugs in R&D, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shumao Ni *Department of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Sheng Ma *Department of Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Yingying YuDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Zhenwen YuValue Pharmaceutical Services Co. Ltd,, Nanjing, China.
Yujia ZhuDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Xiaofen SunDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Lin LiDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Caixia SunDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Hui WangDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Peng PengDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Zheming GuValue Pharmaceutical Services Co. Ltd,, Nanjing, China.
Hua ZhangDepartment of Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Frank WuDepartment of Drug Metabolism and Pharmacokinetics, Clinical, Preparation, Chemistry, TransThera Sciences (Nanjing), Inc., Nanjing, China.
Liyan MiaoDepartment of Pharmacology, the First Affiliated Hospital of Soochow University, Suzhou, China. miaolysuzhou@163.com.
Jean FanTransThera Sciences (US), Inc., Gaithersburg, MD, USA. fan_jean@transtherabio.com.ORCID http://orcid.org/0009-0002-0135-6968

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectiveTinengotinib, a novel multi-target small molecule kinase inhibitor, is currently undergoing phase II clinical trial in the USA and China. The purpose of this open-label study was to investigate the absorption, metabolism, and excretion of [

methodsSix healthy male subjects received a single oral dose of [

resultsTinengotinib was rapidly absorbed in plasma with a time to peak drug concentration (T

conclusionsOverall, tinengotinib demonstrated a complete mass balance with limited renal excretion, no disproportionate blood metabolism, and slow elimination, primarily through the fecal route. The results of this study provide evidence to support the rational use of tinengotinib as a pharmacotherapeutic agent. REGISTRATION: ChinadrugTrials.org.cn identifier: CTR20212852.

Indexed as

BiotransformationHealthy VolunteersProtein Kinase InhibitorsAdministration, OralAdultCarbon RadioisotopesFecesHalf-LifeHumansMalePyridinesTriazolesYoung AdultCarbon RadioisotopesGLPG0634Protein Kinase InhibitorsPyridinesTriazoles

Identifiers

PMID39231890
PMCPMC11455736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.